GLPG3970

DRUG4 trials

Sponsors

Galapagos NV

Conditions

HealthyPrimary Sjögren SyndromeRheumatoid ArthritisUlcerative Colitis

Phase 1

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

CompletedNCT04720183

Galapagos NVHealthy

Start: 2021-01-11End: 2021-04-23Updated: 2024-09-19

Phase 2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

CompletedNCT04577794

Galapagos NVUlcerative Colitis

Start: 2020-10-05End: 2021-05-31Updated: 2023-01-27

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

CompletedNCT04577781

Galapagos NVRheumatoid Arthritis

Start: 2020-10-12End: 2021-04-07Updated: 2022-07-18

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

TerminatedNCT04700280

Galapagos NVPrimary Sjögren Syndrome

Start: 2021-01-28End: 2021-12-27Updated: 2023-09-18

Related Papers

P0111 Differential ex vivo responses to GLPG3970 in bio-naive and bio-experienced biopsies from patients with UC

Journal of Crohn s and Colitis2026-01-01

Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies

Clinical Pharmacology & Therapeutics2024-11-081 citations